AARDVARK THERAPEUTICS, INC. Research and Development Expense
AARDVARK THERAPEUTICS, INC. (AARD) reported Research and Development Expense of $10.46 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- AARDVARK THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $10.46M, a 20.46% decline year-over-year.
- AARDVARK THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $16.57M, a 113.63% increase year-over-year.
- AARDVARK THERAPEUTICS, INC. research and development expense for the quarter ending 2025-12-31 was $14.30M, a 77.36% increase year-over-year.
- AARDVARK THERAPEUTICS, INC. research and development expense for the quarter ending 2025-09-30 was $13.74M, a 237.93% increase year-over-year.
- AARDVARK THERAPEUTICS, INC. research and development expense for fiscal 2025 was $48.94M, a 181.84% increase from fiscal 2024.
- AARDVARK THERAPEUTICS, INC. research and development expense for fiscal 2024 was $17.36M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $10.46M 10-Q · filed 2026-08-11 | $27.02M 10-Q · filed 2026-08-11 | $41.32M derived: sum of 3 quarters · filed 2026-08-11 | $55.06M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $16.57M 10-Q · filed 2026-05-07 | $30.87M derived: sum of 2 quarters · filed 2026-05-07 | $44.60M derived: sum of 3 quarters · filed 2026-05-07 | $57.75M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $14.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $28.04M derived: sum of 2 quarters · filed 2026-03-23 | $41.18M derived: sum of 3 quarters · filed 2026-08-11 | $48.94M 10-K · filed 2026-03-23 |
| 2025-09-30 | $13.74M 10-Q · filed 2025-11-13 | $26.88M derived: sum of 2 quarters · filed 2026-08-11 | $34.64M 10-Q · filed 2025-11-13 | $42.70M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $13.14M 10-Q · filed 2026-08-11 | $20.90M 10-Q · filed 2026-08-11 | $28.96M derived: sum of 3 quarters · filed 2026-08-11 | $33.03M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $7.75M 10-Q · filed 2026-05-07 | $15.82M derived: sum of 2 quarters · filed 2026-05-07 | $19.88M derived: sum of 3 quarters · filed 2026-05-07 | $23.91M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $8.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $12.13M derived: sum of 2 quarters · filed 2026-03-23 | $16.16M derived: sum of 3 quarters · filed 2026-03-23 | $17.36M 10-K · filed 2026-03-23 |
| 2024-09-30 | $4.07M 10-Q · filed 2025-11-13 | $8.09M derived: sum of 2 quarters · filed 2025-11-13 | $9.30M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $4.03M 10-Q · filed 2025-08-13 | $5.24M 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $1.21M 10-Q · filed 2025-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |